Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients-Reference-Cited by-同舟云学术

Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients

Published:2011-01 Issue:1 Volume:35 Page:38-43
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Hayette Sandrine,Chabane Kaddour,Michallet Mauricette,Michallat Estelle,Cony-Makhoul Pascale,Salesse Stéphanie,Maguer-Satta Véronique,Magaud Jean-Pierre,Nicolini Franck E.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference31 articles.

1. Src family kinases, key regulators of signal transduction;Parsons;Oncogene,2004

2. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells;Danhauser-Riedl;Cancer Res,1996

3. Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth;Roginskaya;Leukemia,1999

4. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells;Ptasznik;Nat Med,2004

5. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells;Wu;Blood,2008

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hemopoietic Cell Kinase amplification with Protein Tyrosine Phosphatase Receptor T depletion leads to polycythemia, aberrant marrow erythoid maturation, and splenomegaly;Scientific Reports;2019-05-07

2. A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML;Leukemia Research;2019-03

3. Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK ‐ ERK and NF ‐κB pathways in a model of chronic myeloid leukemia;Molecular Oncology;2018-04-06

4. A new mechanism of resistance to ABL1 tyrosine kinase inhibitors in a BCR-ABL1-positive cell line;Leukemia Research;2017-10

5. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia;Haematologica;2017-06-08